Intensity-Modulated Radiation Therapy for Nasopharyngeal Cancer
This trial is testing the side effects and best dose of birinapant given with IMRRT for head and neck squamous cell carcinoma that has come back. Birinapant may stop the growth of tumor cells by blocking IAP, a protein needed for tumor cell survival. IMRRT uses thin beams of radiation of different intensities that are aimed at the tumor from many angles. This type of re-irradiation therapy reduces the damage to healthy tissue near the tumor. Giving birinapant with IMRRT may lower the chance of head and neck squamous cell carcinoma growing or spreading.
- Head and Neck Squamous Cell Carcinoma
- Nasopharyngeal Cancer
- Sinonasal Squamous Cell Carcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2013 Phase 3 trial • 637 Patients • NCT00884741
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What key goals is this research trying to achieve?
"This trial, which will be tracked for up to 42 days, seeks to measure the occurrence of dose-limiting toxicities and other adverse reactions. Secondary goals are observing change in caspase 3 levels (i.e., increase in apoptosis/necroptosis marker), overall survival estimates at maximum tolerated dose level with 95% two-sided confidence interval, and FADD copy gain within tumor tissue or blood as an exploratory analysis into its association with response rate."
How many participants can join this medical trial?
"Affirmative. Clinicaltrials.gov's information indicates that this medical investigation is still looking for participants, originally posted on July 1st 2019 and most recently updated October 6th 2022. This trial requires the recruitment of 34 subjects across 21 distinct sites."
Is this research actively seeking volunteers?
"Correct. Data hosted on clinicaltrials.gov points to this medical study as actively seeking participants - it was initially posted on July 1st 2019 and last modified October 6th 2022. 34 people across 21 different centres are required for the trial's completion."
Has the FDA sanctioned Intensity-Modulated Radiation Therapy?
"The safety of Intensity-Modulated Radiation Therapy was judged to be a 1, considering that this is merely a Phase 1 medical trial with minimal data regarding its efficacy and security."
How many venues is this experiment taking place in?
"The full list of trial sites recruiting patients includes the University of Kansas Cancer Center at North Kansas City Hospital in North Kansas City, UM Sylvester Comprehensive Cancer Center at Deerfield Beach in Deerfield Beach, and HaysMed University of Kansas Health System in Hays. Additionally, there are 18 other medical centres participating as well."
Are other investigators looking into the potential of Intensity-Modulated Radiation Therapy?
"Currently, two ongoing studies are exploring the potential of Intensity-Modulated Radiation Therapy. Neither is in Phase 3 yet. As for geographical data, 43 clinical trial sites across America are looking into this form of therapy; most notably within Sarasota, Florida."